Lantern Pharma ( NASDAQ: LTRN ) announced results from the initial patient group in the ongoing mid-stage trial for LP-300, in combination with pemetrexed and carboplatin in never smokers with advanced non-small cell lung cancer who have progressed after receiving treatment with a tyrosine kinase inhibitor. In the Phase 2 lead-in cohort of 7 patients, 6 patients experienced clinical benefit from the combination of LP-300 and chemotherapy while 1 patient experienced progressive disease. Of the 6 patients experiencing clinical benefit – 3 patients showed partial responses with an average tumor size reduction of 51% and 3 patients have stable disease with an average tumor size reduction of 13%.
The clinical benefit rate and disease control rate is 86% for this group with an objective response rate of 43%. A preliminary analysis of data indicates no additional safety concerns with no observed dose limiting toxicities and no reported treatment-related serious adverse events Source: Press Release More on Lantern Pharma Seeking Alpha’s Quant Rating on Lantern Pharma Historical earnings data for Lantern Pharma Financial information for Lantern Pharma.
